Do you want to start trading the Zynerba Pharmaceuticals share price online? In this article, we will give you all the knowledge you need to set up your analysis of this stock. We will explain who this company is and what are its different activities. We will then study its sector of activity with a presentation of its main competitors on the market. Of course, we will also discuss its allies with some examples of partnerships recently set up by this group. But first, we will give you some keys to succeed in your fundamental analysis of this stock by listing the elements you will need in this context.
You will need to focus on the ongoing development of drug candidates by this company with the follow-up of the different phases of clinical trials and, finally, the obtaining of marketing authorizations.
The various partnerships, whether they are research partnerships or funding partnerships, will of course also be important when you are looking at the likelihood of this value changing.
We will be watching to see if this business becomes profitable in the near future as the group begins to commercialize the products developed.
Finally, you should also closely monitor the company's direct and indirect competition by reading the publications and news of major groups developing similar products.
Let's take a look at Zynerba Pharmaceuticals and what it does. You need to know all of this before you start trading in order to understand the major issues and potential threats.
The Zynerba Pharmaceuticals Group is an Italian-American pharmaceutical company. Specifically, the group is engaged in the research and development and commercialization of transdermal synthetic cannabinoid treatments for patients with significant unmet needs.
The group has a development pipeline that includes two major product candidates with ZYN002 and ZYN001.
ZYN002 is a synthetic cannabidiol or CBD and a non-psychoactive cannabinoid. It is formulated from a patent-protected gel and enhanced by permeation to allow transdermal delivery through the skin and circulatory system. This treatment candidate is currently in Phase II clinical development and is being tested in patients with refractory epilepsy, osteoarthritis of the knee and Fragile X syndrome.
The other treatment candidate, ZYN001, is a tetrahydrocannabinol or THC prodrug. It allows for transdermal delivery through the skin and into the circulatory system via a patch. This treatment primarily targets two pain indications related to fibromyalgia and peripheral neuropathic pain.
Currently, the Zynerba Pharmaceuticals group has 28 employees.
After having familiarized ourselves with the main activities of the Zynerba Pharmaceuticals group, we propose that you discover its direct and indirect competitors in its sector of activity:
This company, also known as Inovio, is a biotechnology company that develops and participates in the development of deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on the treatment and prevention of cancers and infectious diseases.
This immunotherapy company focuses on the research, development and sale of therapies to treat various diseases including cancer.
This is a subsidiary of the American group Gilead Sciences which develops immunotherapy products against cancer, mainly through therapy with autologous T cells genetically modified with chimeric antigen receptors.
This is another American biotech company specializing in the development of gene therapies for the treatment of severe genetic disorders and cancer.
This company is a clinical-stage immunotherapy company focused on optimizing the body's innate and adaptive immune responses through the stimulation of toll-like receptors.
This is the latest competitor to Zynerba in terms of capitalization. This company is a biopharmaceutical company formed in 2013 by a collaboration of Fred Htchinson Cancer Research Center and Memorial Sloan-Kettering Cancer Center and pediatric partner Seattle Children's Research Institute. Its goal is to develop a pipeline of cancer immunotherapy drugs.
Zynerba Pharmaceuticals is a biotech company and as such, it needs to set up certain partnerships with outside entities in order to boost its research advances. We will present here a partnership that this company has put in place over the past few years.
In 2019, the Zynerba Pharmaceuticals group set up a research partnership with the University of California in an effort to prove that CBD could be converted to THC. In this study, CBD was exposed to stomach fluid without enzymes for three hours. The results showed that after 120 minutes, 98% of the CBD was degraded. Most of what remained was delta-9-THC and delta-8-THC. The final sample was analyzed here by chromatography and mass spectrometry to ensure better accuracy.
Since its 2015 IPO, Zynerba's stock has rather followed a bearish underlying trend as its listing has gone from $16.25 to $4.15 in 5 years. However, several bullish spikes could be observed during this period with a high reached at $36.49 shortly after its first listing and a low hit in 2018 at $2.92.
Yes, it is better to invest in this stock through CFDs or Contracts for Difference, as Zynerba Group does not currently make a profit and therefore does not pay a dividend to its shareholders. With CFDs, you can simply speculate on the rise or fall of its price.
As part of your technical analysis of the Zynerba share, we recommend that you use several chart indicators that you can display on the real-time charts of your trading platform, including volatility indicators and possible trend reversal points.
eToro is a multi-asset platform which offers both investing in stocks and cryptoassets, as well as trading CFDs.
Please note that CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail CFD accounts lose money. You should consider whether you can afford to take the high risk of losing your money.
Past performance is not an indication of future results. Trading history presented is less than 5 complete years and may not suffice as basis for investment decision.
Copy trading is a portfolio management service, provided by eToro (Europe) Ltd., which is authorised and regulated by the Cyprus Securities and Exchange Commission.
Cryptoasset investing is unregulated in some EU countries and the UK. No consumer protection. Your capital is at risk.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro.
